RIKEN and The University of Tokyo release full-length human cDNA clones

The set of 80,000 full-length human cDNA, which covers nearly the entire human genome, was made available on 15 March 2010 for general use through the RIKEN BioResource Center (BRC).

Initiated in 2004 on the heels of the first complete sequencing of the human genome, the GNP aims to clarify the structure of gene and protein–protein interactions toward applications in treatment and drug development.

By its completion in 2008, the project had succeeded in generating important scientific findings, producing vast amounts of experimental data in the process. To organize this data, the GNP created the Genome Network Platform, a visual interface enabling users to search genes, browse the genome, and analyze expression profiles.

It is through this platform that the 80,000 full-length human cDNA clones are being released. Two types of clones make up this new resource: a collection of 30,000 full-length human cDNA clones compiled by groups at The University of Tokyo and the RIKEN Omics Science Center, and 50,000 Gateway® entry clones reconstructed based on the cDNA clones. The Gateway® entry clones include clones made from cDNA created by the Research Association for Biotechnology under the New Energy and Industrial Technology Development Organization (NEDO) Full-length Human cDNA Sequencing Project. Researchers interested in obtaining the cDNA clones from either of these sets should visit the website of the Genome Network Platform (genomenetwork.nig.ac.jp), operated by the National Institute of Genetics, and place an order through the RIKEN BRC. Details on ordering cDNA clones can be found at the BRC’s DNA Bank website (www.brc.riken.jp/lab/dna/en/GNPcloneen.html).

Full-length cDNA clones offer researchers a powerful means to investigate the expression of messenger RNA, study proteins and especially protein function, and isolate specific genes. As one of the most important basic resources for genomic research, the provision of these new clones offers a valuable opportunity for researchers, promising key advances in treatment and drug discovery.